A recent report prepared by the Analysis Group sought to describe the current pipeline of biopharmaceuticals under development that could benefit US-based patients within the next 5 to 10 years.
A recent report prepared by the Analysis Group sought to describe the current pipeline of biopharmaceuticals under development that could benefit US-based patients within the next 5 to 10 years.
Drawing on data from the Evaluate Pharma database—which curates publicly available information on companies and their products—as well as FDA data, the researchers identified new medicines under development or regulatory review as of August 2016, and found 6300 biopharmaceutical products (unique molecules) in global clinical development or under regulatory review that were a part of over 9500 projects (unique molecule-indication combinations). A range of projects explored novel scientific approaches in clinical development, including gene therapy, cell therapy, DNA and RNA therapy, and conjugated monoclonal antibodies (which use monoclonal antibodies joined to chemotherapy agents or other drugs to target specific cells, such as cancer cells).
While the projects in question address a variety of therapeutic areas, the report shows a robust number of projects targeting the underserved population of diabetes patients—the report found a total of 749 projects and 432 products for the treatment of diabetes or diabetes-related complications:
• 482 preclinical projects
• 97 phase 1 projects
• 125 phase 2 projects
• 42 phase 3 projects
• 3 projects filed with the FDA as of August 2016
Of the diabetes projects identified, 599 have the potential to result in the first products of a unique pharmacological class. A majority of the diabetes-focused projects seeking to be first-in-class are in preclinical research, with 16 projects in phase 3 trials.
The report also identifies 11 projects and 10 unique products intended to treat diabetes or diabetes-related complications that are designated as orphan projects. However, the authors point out that its count of orphan-designated medicines under development may be low, as early-stage projects may not yet have orphan designation.
While the number of projects in the diabetes biopharmaceutical pipeline is promising, the authors remind their audience that, of the investigational compounds that eventually reach clinical trials, only 12% are ultimately approved by the FDA (after 10 to 15 years of testing and an average of $2.6 billion in development costs). Clinical trials have become increasingly complex in recent years, the authors note; compared with the period from 2001 to 2005, the period from 2011 to 2015 saw the mean number of total endpoints in a typical phase 3 trial protocol increase by 86%, and the total number of procedures (such as blood work and exams) conducted during such trials increase by 70%. The authors suggest that such a trend could lead to longer timeframes and increased costs for drug approvals unless efficiency measures can be properly implemented.
The authors conclude that, while it is impossible to accurately predict which projects and products under development will eventually reach patient populations, the current pipeline for biopharmaceuticals, including those intended to address the needs of patients with diabetes, is both extensive and innovative. While the need for continued development of new treatments for US patients remains high, the current pipeline, they say, “is laying the groundwork for tomorrow’s breakthrough therapies for patients with few other therapeutic alternatives.”
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.